- Conditions
- Lung Cancer
- Interventions
- Temozolomide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1321–1344
of 4,379
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Small Cell Lung Cancer
- Interventions
- INNO-206
- Drug
- Lead sponsor
- CytRx
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Billings, Montana • Albany, New York + 4 more
- Conditions
- Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer
- Interventions
- BBI-355, Erlotinib, Futibatinib, BBI-825
- Drug
- Lead sponsor
- Boundless Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Santa Monica, California • Denver, Colorado + 12 more
- Conditions
- Carcinoma, Non-small-cell Lung
- Interventions
- Epothilone
- Drug
- Lead sponsor
- R-Pharm
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Sacramento, California • Miami Beach, Florida + 12 more
- Conditions
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Durvalumab, Danvatirsen, Oleclumab, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Pittsburgh, Pennsylvania • Nashville, Tennessee
- Conditions
- Lung Cancer
- Interventions
- carboplatin, chemotherapy, efaproxiral, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 6 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, paclitaxel, rebimastat
- Drug
- Lead sponsor
- NCIC Clinical Trials Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 774 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 12 more
- Conditions
- Lung Cancer, Non-Small Cell Lung Cancer
- Interventions
- BMS-986205, Nivolumab, Chemotherapy
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 19
- States / cities
- San Diego, California • Fort Myers, Florida • Jacksonville, Florida + 16 more
- Conditions
- Bladder Cancer, Kidney Cancer, Lung Cancer
- Interventions
- tucotuzumab celmoleukin
- Biological
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • New York, New York
- Conditions
- Advanced Solid Tumor Cancer
- Interventions
- ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
- Drug
- Lead sponsor
- Calico Life Sciences LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • New Haven, Connecticut • Baltimore, Maryland + 11 more
- Conditions
- Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab
- Drug · Other · Procedure + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
- Interventions
- Avelumab Phase 1b, Talazoparib Phase 1b, Avelumab Phase 2, Talazoparib Phase 2
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 38
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 12 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Nivolumab, Ipilimumab, Carboplatin, Paclitaxel, Pemetrexed
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey
- Conditions
- Carcinoma, Pancreatic Ductal, Mesothelioma, Ovarian Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- Amatuximab (MORab-009)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lung Cancer
- Interventions
- Bexarotene, Erlotinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non Small Cell Lung Cancer (NSCLC)
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 127
- States / cities
- Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 117 more
- Conditions
- Non-small Cell Lung Cancer, Metastatic Lung Cancer
- Interventions
- Pembrolizumab + Pemetrexed-Platinum, Pemetrexed-Platinum
- Drug
- Lead sponsor
- Aetion, Inc.
- Other
- Eligibility
- Not listed
- Enrollment
- 1,854 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lung Cancer
- Interventions
- educational intervention, medical chart review, questionnaire administration, end-of-life treatment/management, psychosocial assessment and care, quality-of-life assessment, management of therapy complications, assessment of therapy complications
- Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Lung Non-Small Cell Carcinoma, Thoracic Cancer
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
- Interventions
- Nivolumab, (8gy x 3), Platinum Doublet
- Drug · Radiation
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Capmatinib, Nazartinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 12
- States / cities
- Washington D.C., District of Columbia • Athens, Georgia • Lexington, Kentucky + 8 more
- Conditions
- Non-Small Cell Lung Cancer - Completely Resectable
- Interventions
- L-Vax: Autologous, DNP-Modified NSCLC Vaccine
- Biological
- Lead sponsor
- AVAX Technologies
- Industry
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 2
- States / cities
- Fayetteville, Arkansas • Philadelphia, Pennsylvania
- Conditions
- Lung Cancer
- Interventions
- bevacizumab, vinorelbine tartrate
- Biological · Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 70 Years to 120 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Rochester, New York